WO2004013349A3 - Method for examining and evaluating virus enzymes in high throughput screening (hts) - Google Patents

Method for examining and evaluating virus enzymes in high throughput screening (hts) Download PDF

Info

Publication number
WO2004013349A3
WO2004013349A3 PCT/EP2003/007680 EP0307680W WO2004013349A3 WO 2004013349 A3 WO2004013349 A3 WO 2004013349A3 EP 0307680 W EP0307680 W EP 0307680W WO 2004013349 A3 WO2004013349 A3 WO 2004013349A3
Authority
WO
WIPO (PCT)
Prior art keywords
hts
high throughput
throughput screening
examining
activity
Prior art date
Application number
PCT/EP2003/007680
Other languages
German (de)
French (fr)
Other versions
WO2004013349A2 (en
Inventor
Thorsten Schmidt
Original Assignee
Bayer Healthcare Ag
Thorsten Schmidt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Thorsten Schmidt filed Critical Bayer Healthcare Ag
Priority to AU2003250068A priority Critical patent/AU2003250068A1/en
Publication of WO2004013349A2 publication Critical patent/WO2004013349A2/en
Publication of WO2004013349A3 publication Critical patent/WO2004013349A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to cell culture systems used to examine the activity of viral proteases NS2/3 and NS3/4A of the hepatitis C virus (HCV) and to identify substances in high throughput screening (HTS) which modulate the activity of the proteases. The system has a modular design and makes examination possible for cis-cleavage activity and trans-cleavage activity according to protease type and structure.
PCT/EP2003/007680 2002-07-29 2003-07-16 Method for examining and evaluating virus enzymes in high throughput screening (hts) WO2004013349A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003250068A AU2003250068A1 (en) 2002-07-29 2003-07-16 Method for examining and evaluating virus enzymes in high throughput screening (hts)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10234418.3 2002-07-29
DE2002134418 DE10234418A1 (en) 2002-07-29 2002-07-29 Procedure for the examination and assessment of virus enzymes in HTS

Publications (2)

Publication Number Publication Date
WO2004013349A2 WO2004013349A2 (en) 2004-02-12
WO2004013349A3 true WO2004013349A3 (en) 2004-04-15

Family

ID=30128469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007680 WO2004013349A2 (en) 2002-07-29 2003-07-16 Method for examining and evaluating virus enzymes in high throughput screening (hts)

Country Status (3)

Country Link
AU (1) AU2003250068A1 (en)
DE (1) DE10234418A1 (en)
WO (1) WO2004013349A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000548A1 (en) * 1996-06-28 1998-01-08 Lg Chemicals Co., Ltd. Hepatitis c surrogate virus for testing the activity of hepatitis c virus protease, a recombinant gene and a use thereof
WO2000008469A1 (en) * 1998-08-05 2000-02-17 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis c virus protease
WO2000066623A2 (en) * 1999-05-04 2000-11-09 Boehringer Ingelheim (Canada) Ltd. Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000548A1 (en) * 1996-06-28 1998-01-08 Lg Chemicals Co., Ltd. Hepatitis c surrogate virus for testing the activity of hepatitis c virus protease, a recombinant gene and a use thereof
WO2000008469A1 (en) * 1998-08-05 2000-02-17 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the hepatitis c virus protease
WO2000066623A2 (en) * 1999-05-04 2000-11-09 Boehringer Ingelheim (Canada) Ltd. Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHO Y-G ET AL: "IN VIVO ASSAY FOR HEPATITIS C VIRAL SERINE PROTEASE ACTIVITY USING A SECRETED PROTEIN", JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 72, no. 1, 1998, pages 109 - 115, XP000979032, ISSN: 0166-0934 *
CHO YOUNG-GYU ET AL: "Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity", JOURNAL OF VIROLOGICAL METHODS, vol. 65, no. 2, 1997, pages 201 - 207, XP002267863, ISSN: 0166-0934 *
DOWNES MICHAEL ET AL: "Two receptor interaction domains in the corepressor, N-CoR/RIP13, are required for an efficient interaction with Rev-erbA-alpha and RVR: Physical association is dependent on the E region of the orphan receptors", NUCLEIC ACIDS RESEARCH, vol. 24, no. 22, 1996, pages 4379 - 4386, XP001156849, ISSN: 0305-1048 *
FORNS X ET AL: "Characterization of Modified Hepatitis C Virus E2 Proteins Expressed on the Cell Surface", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 274, no. 1, 15 August 2000 (2000-08-15), pages 75 - 85, XP004435955, ISSN: 0042-6822 *
HIROWATARI Y ET AL: "A novel method for analysis of viral proteinase activity encoded by hepatitus C virus in cultured cells", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 225, 1995, pages 113 - 120, XP002096985, ISSN: 0003-2697 *
KIM SUNG YUN ET AL: "In vivo determination of substrate specificity of hepatitis C virus NS3 protease: Genetic assay for site-specific proteolysis", ANALYTICAL BIOCHEMISTRY, vol. 284, no. 1, 15 August 2000 (2000-08-15), pages 42 - 48, XP001156846, ISSN: 0003-2697 *

Also Published As

Publication number Publication date
AU2003250068A1 (en) 2004-02-23
DE10234418A1 (en) 2004-02-12
WO2004013349A2 (en) 2004-02-12
AU2003250068A8 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
HK1125360A1 (en) Compounds and methods for inhibiting hepatitis c viral replication
Tautz et al. Pathogenesis of mucosal disease, a deadly disease of cattle caused by a pestivirus
TR199901602T2 (en) Inhibitors of serine proteases and in particular the hepatitis C virus NS3 protease.
MX9708678A (en) Soluble, active hepatitis c virus protease.
AU2003284689A1 (en) NUCLEIC ACID CONSTRUCT CONTAINING HEPATITIS C VIRUS (HCV) OF GENOCYPE 2a GENOME-ORIGIN NUCLEIC ACID AND CELL HAVING THE NUCLEIC ACID CONSTRUCT TRANSFERRED THEREINTO
HUP0200945A2 (en) Surrogate cell-based system and method for assaying the activity of hapatitis c virus ns3 protease
Petricevich et al. Inhibitory potential of Crotalus durissus terrificus venom on measles virus growth
Maharaj et al. N-linked glycosylation of the West Nile virus envelope protein is not a requisite for avian virulence or vector competence
WO2004013349A3 (en) Method for examining and evaluating virus enzymes in high throughput screening (hts)
Schrauf et al. Extension of flavivirus protein C differentially affects early RNA synthesis and growth in mammalian and arthropod host cells
Filocamo et al. Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus
WO1998037180A3 (en) Hcv fusion protease and polynucleotide encoding same
Ramirez et al. Efficient culture of SARS-CoV-2 in human hepatoma cells enhances viability of the virus in human lung cancer cell lines permitting the screening of antiviral compounds
Bessaud et al. Identification and enzymatic characterization of NS2B–NS3 protease of Alkhurma virus, a class-4 flavivirus
WO2003063783A3 (en) Multiple virus replicon culture systems
Centers for Disease Control and Prevention (CDC Outbreak of influenza A infection among travelers--Alaska and the Yukon Territory, May-June 1999
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
KR980002263A (en) Hepatitis C virus alternative virus capable of measuring protease activity of hepatitis C virus, its recombinant gene and its use
AU4397097A (en) Soluble polypeptides with activity of the ns3 serine protease of hepatitis c virus, and process for their preparation and isolation
CA2445911A1 (en) Methods for the identification of antiviral compounds
WO2002072776A3 (en) Cell culture system for synthesis of infectious hepatitis c virus
Lindenbach et al. Evasive maneuvers by hepatitits C virus
AU6754196A (en) Novel fluorescent substrate for assaying activity of hepatitis c virus ns3 serine protease
Yasmin et al. Antiviral activity of thiazolide derivatives against dengue virus in Huh-7 cell line
ATE359293T1 (en) PEPTIDES DERIVED FROM EPSTEIN-BARR VIRUS VCA-P18 CAPSID ANTIGEN AND USE THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP